Triple Negative Breast Cancer Trial

Breast Cancer Clinical Trial

— TNT  

Official title:

Triple Negative Trial: A Randomised Phase III Trial of Carboplatin Compared to Docetaxel for Patients With Metastatic or Recurrent Locally Advanced ER-, PR- and HER2- Breast Cancer.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00532727
• Other study ID #: ICR-CTSU/2006/10003
• Secondary ID: ISRCTN97330959Ma
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: January 2008
• Est. completion date: March 2020

Study information

• Verified date: February 2019
• Source: Institute of Cancer Research, United Kingdom
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether there is greater activity for carboplatin than a taxane standard of care (docetaxel) in women with ER-, PR- and HER2- breast cancer. The trial aims to recruit between 370 and 450 patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 400
• Est. completion date: March 2020
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed ER-, PR-, primary breast cancer

• Histologically confirmed HER2- primary breast cancer

• Measurable confirmed metastatic or recurrent locally advanced disease unsuitable for local therapy but suitable for taxane chemotherapy

• Patients with stable, treated bain metastases will be eligible providing informed consent can be given and that other sites of measurable disease are present.

• Patients with bone metastases currently receiving bisphosphonates for palliation will be eligible providing informed consent can be given and that other sites of measurable disease are present

• ECOG Performance Status 0, 1, or 2

• Adequate haematology, biochemical indices (FBC, U & Es)

• LFTs = Normal bilirubin, AST and/or ALT = 3 x ULN if Alk Phos >5 x ULN (or an isolated elevation AST/ALT of =5 x ULN

• Adequate renal function - Creatinine clearance of >25mls per minute

• Written informed consent, able to comply with treatment and follow up

Exclusion Criteria:

• Original primary tumour or subsequent relapse known to be positive for any of ER, PR, or HER2 receptors

• Patients unfit for chemotherapy or those with neuropathy >grade 1 (sensory or motor)

• Known allergy to platinum compounds or to mannitol

• Known sensitivity to taxanes

• Patients with inoperable locally advanced disease suitable for local radiotherapy or an anthracycline containing regimen

• Previous chemotherapy for metastatic disease other than an anthracycline as in inclusion criteria above

• Previous exposure to a taxane in adjuvant chemotherapy within 12 months of trial entry

• Previous treatment with a taxane for recurrent locally advanced disease

• Previous treatment with a platinum chemotherapy drug

• LFTs = Abnormal bilirubin (> ULN), AST and/or ALT >3 X ULN and Alk Phos >5 x ULN (or an isolated elevation AST/ALT of >5 x ULN)

• Patients with a life expectancy of less than 3 months

• Previous malignancies other than adequately treated in situ carcinoma of the uterine cervix or basal or squamous call carcinoma of the skin, unless there has been a disease free interval of at least 10 years

• Previous or synchronous second breast cancer (unless also confirmed ER-, PR- and HER2-)

• Patients with bone limited disease

• Other serious uncontrolled medical conditions or concurrent medical illness likely to compromise life expectancy and/or the completion of trial therapy

• Pregnant, lactating or potentially childbearing women not using adequate contraception

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Carboplatin
AUC 6 every 3 weeks for six cycles (18 weeks)
• Docetaxel
100mg/m2 every 3 weeks for six cycles (18 weeks)

Locations

Country	Name	City	State
United Kingdom	Guy's and St Thomas' Hospital NHS Foundation Trust	London

Sponsors (4)

Lead Sponsor	Collaborator
Institute of Cancer Research, United Kingdom	Breakthrough Breast Cancer, Cancer Research UK, King's College London

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response: Response will be evaluated after three and six cycles of chemotherapy using modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria, with appropriate clinical assessment and radiological investigations.		Time from start of treatment to 18 weeks
Secondary	Time to progression: this will be defined according to RECIST criteria and will be measured from the start of treatment until the confirmation of progression		Time from start of treatment until confirmation of progression
Secondary	Progression free survival: this will be defined according to RECIST criteria and will be measured from the start of treatment until the confirmation of progression or death.		Time from start of treatment until confirmation of progression or death
Secondary	Time to treatment failure: this will be defined as time from randomisation to discontinuation of protocol treatment for any reason, or progression of disease as defined by RECIST		Time from randomisation to discontinuation of protocol treatment for any reason, or progression of disease
Secondary	Overall survival: this will be defined as time from randomisation until death from any cause in the intention to treat population		Time from randomisation until death from any cause
Secondary	Toxicity will be assessed throughout the treatment period using the National Cancer Institute Common Terminology Criteria for Adverse Events version three (NCI CTCAE v3.0)		Time from start of treatment to 18 weeks

External Links

•   Link